UAI-201

UAI-201 is a potent, orally bioavailable small molecule inhibitor of the B-Raf kinase, specifically targeting the V600E mutation. Developed by YOUAI Co. Ltd., it is designed to treat various solid tumors, including melanoma and colorectal cancer, where B-Raf mutations drive constitutive activation of the MAPK signaling pathway. Preclinical data presented at AACR 2012 demonstrated that UAI-201 effectively inhibits the phosphorylation of MEK and ERK, leading to significant tumor growth inhibition in xenograft models without the paradoxical MAPK activation observed with some other Raf inhibitors. The compound also showed a favorable safety profile in normal cell lines and acceptable pharmacokinetic properties.